Published in Int J Oncol on November 01, 2007
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J (2012) 1.57
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther (2009) 1.14
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med (2011) 1.01
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther (2010) 0.98
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol Ther (2010) 0.95
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Mol Pharmacol (2010) 0.94
MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol (2014) 0.93
Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biol Ther (2013) 0.92
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs (2010) 0.91
Inhibition of autophagy by 3-MA enhances IL-24-induced apoptosis in human oral squamous cell carcinoma cells. J Exp Clin Cancer Res (2015) 0.90
Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res (2013) 0.89
Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res (2008) 0.88
MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells. Mol Cells (2012) 0.88
Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes. Adv Cancer Res (2012) 0.88
Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV). J Cell Physiol (2014) 0.86
Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer (2013) 0.85
The p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA. PLoS One (2010) 0.84
IL-24: a classic cytokine and/or a potential cure for cancer? J Cell Mol Med (2008) 0.84
Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol (2015) 0.83
Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities. J Mol Signal (2013) 0.81
Interleukin-24 is correlated with differentiation and lymph node numbers in rectal cancer. World J Gastroenterol (2011) 0.80
Myeloid cells migrate in response to IL-24. Cytokine (2011) 0.80
Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol (2010) 0.80
Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines. World J Gastroenterol (2010) 0.79
Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells. Cytokine (2011) 0.79
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol (2012) 0.78
MDA-7/IL-24 inhibits cell survival by inducing apoptosis in nasopharyngeal carcinoma. Int J Clin Exp Med (2014) 0.77
Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer. PLoS One (2012) 0.77
Update on oncolytic viral therapy - targeting angiogenesis. Onco Targets Ther (2013) 0.77
Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anticancer Agents Med Chem (2012) 0.77
Molecular Mechanisms Governing IL-24 Gene Expression. Immune Netw (2012) 0.76
Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells. J Cancer Res Clin Oncol (2015) 0.76
Targeting eradication of chronic myeloid leukemia using chimeric oncolytic adenovirus to drive IL-24 expression. Int J Clin Exp Pathol (2015) 0.75
Alteration of Gene Expression Profile in Kidney of Spontaneously Hypertensive Rats Treated with Protein Hydrolysate of Blue Mussel (Mytilus edulis) by DNA Microarray Analysis. PLoS One (2015) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature (2007) 8.87
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 7.19
Interlinked fast and slow positive feedback loops drive reliable cell decisions. Science (2005) 6.88
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Interleukin-10 and related cytokines and receptors. Annu Rev Immunol (2004) 5.41
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Buonocore memorial lecture. Adhesion to enamel and dentin: current status and future challenges. Oper Dent (2003) 4.75
Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol (2013) 4.04
mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A (2002) 3.99
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res (2007) 3.92
Spontaneous cell polarization through actomyosin-based delivery of the Cdc42 GTPase. Science (2003) 3.92
Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest (2007) 3.89
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast. Nature (2010) 3.72
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell (2008) 3.26
Bile acids as regulatory molecules. J Lipid Res (2009) 3.23
MAPK pathways in radiation responses. Oncogene (2003) 3.12
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation (2008) 2.98
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther (2008) 2.96
Vorinostat. Nat Rev Drug Discov (2007) 2.83
New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res (2010) 2.82
The structural basis of actin filament branching by the Arp2/3 complex. J Cell Biol (2008) 2.82
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
The RickA protein of Rickettsia conorii activates the Arp2/3 complex. Nature (2004) 2.73
Motility and segregation of Hsp104-associated protein aggregates in budding yeast. Cell (2011) 2.72
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p. Cell Host Microbe (2008) 2.68
Endocytosis optimizes the dynamic localization of membrane proteins that regulate cortical polarity. Cell (2007) 2.61
Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res (2006) 2.60
Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene (2005) 2.58
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
Robust cell polarity is a dynamic state established by coupling transport and GTPase signaling. J Cell Biol (2004) 2.56
Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 2.49
Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res (2008) 2.45
Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood (2010) 2.45
Rho1 directs formin-mediated actin ring assembly during budding yeast cytokinesis. Curr Biol (2002) 2.38
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A (2006) 2.38
Attenuation of estrogen receptor alpha-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor. Genes Dev (2004) 2.35
The Arp2/3 complex is required for lamellipodia extension and directional fibroblast cell migration. J Cell Biol (2012) 2.34
Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature (2002) 2.32
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res (2003) 2.30
Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell (2009) 2.28
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 2.27
The Ran GTPase mediates chromatin signaling to control cortical polarity during polar body extrusion in mouse oocytes. Dev Cell (2007) 2.27
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res (2004) 2.23
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood (2008) 2.22
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem (2004) 2.18
ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest (2008) 2.16
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13